TD Asset Management
VIR icon

TD Asset Management’s Vir Biotechnology VIR Stock Holding History

TD Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,600
Closed -$702K – 1455
2023
Q2 		$702K Buy
+28,600
New +$718K ﹤0.01% 1199
2022
Q2 		– Sell
-21,400
Closed -$550K – 1520
2022
Q1 		$550K Sell
21,400
-19,100
-47% -$566K ﹤0.01% 1334
2021
Q4 		$1.7M Buy
+40,500
New +$1.59M ﹤0.01% 1171

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's VIR Position: Q3 2023 in Review

TD Asset Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 28,600 shares — an estimated $702K sold.

TD Asset Management first reported a position in VIR in Q4 2021 and held it in 3 quarters. The position peaked at $1.7M in Q4 2021. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • TD Asset Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • TD Asset Management sold 28,600 Vir Biotechnology shares in Q3 2023, an estimated $702K.
  • TD Asset Management first reported a position in Vir Biotechnology in Q4 2021 and held it in 3 quarters.
  • TD Asset Management's Vir Biotechnology position peaked at $1.7M in Q4 2021.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.